Serum protein acidic and rich in cysteine (SPARC) as a prognostic marker in soft tissue sarcomas

Persistent Link:
http://hdl.handle.net/10150/610120
Title:
Serum protein acidic and rich in cysteine (SPARC) as a prognostic marker in soft tissue sarcomas
Author:
Morgan, Sherif; Nagle, Raymond; Cranmer, Lee
Affiliation:
The University of Arizona Cancer Center, 1515 N. Campbell Avenue, Tucson, AZ, USA; Department of Pathology, University of Arizona, Tucson, AZ, USA
Issue Date:
2014
Publisher:
BioMed Central
Citation:
Morgan et al. Clinical Sarcoma Research 2014, 4:2 http://www.clinicalsarcomaresearch.com/content/4/1/2
Journal:
Clinical Sarcoma Research
Rights:
© 2014 Morgan et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0)
Collection Information:
This item is part of the UA Faculty Publications collection. For more information this item or other items in the UA Campus Repository, contact the University of Arizona Libraries at repository@u.library.arizona.edu.
Abstract:
BACKGROUND:Serum protein acidic and rich in cysteine (SPARC) is a matricellular secreted glycoprotein that performs several cellular functions and has been implicated in tumorigenesis in a variety of tumor types. The chemotherapeutic agent nanoparticle albumin-encapsulated (NAB)-paclitaxel has been postulated to exploit SPARC expression to target neoplastic cells. SPARC's role, and potentially the role of NAB-paclitaxel, in the highly heterogeneous class of soft-tissue sarcomas (STS) has not been investigated. Our objective was to explore the pattern of SPARC expression and its prognostic significance in STS.METHODS:27 tissue specimens representing various STS histologies were stained for SPARC expression by immunohistochemistry (IHC). Staining intensity was scored blindly. Survival was determined from patients' medical records and analyzed using Kaplan-Meier and log-rank with respect to SPARC expression level.RESULTS:Elevated SPARC expression was observed in 15/27 (56%) specimens. Overall patient survival segregated strongly based on levels of SPARC expression. Patients who expressed low-to-moderate levels of SPARC exhibited median survival of 22.1months, while the median survival of patients with moderate-to-high expression levels was 4.4months (log rank; p=0.0016).CONCLUSIONS:SPARC expression is elevated in a significant proportion of STS specimens analyzed in this study, but it does not appear to correlate with specific STS histologies. Given our limited sample size, we cannot draw definitive conclusions regarding association of SPARC with STS subtype. Overall survival segregates strongly by degree of SPARC expression, with elevated expression being adverse. If validated in a larger study, our results suggest that trials in STS with agents potentially targeting SPARC, such as NAB-paclitaxel, should be stratified by SPARC expression level.
EISSN:
2045-3329
DOI:
10.1186/2045-3329-4-2
Keywords:
Soft-tissue sarcoma; SPARC; Nanoparticle albumin-encapsulated (NAB)-paclitaxel
Version:
Final published version
Additional Links:
http://www.clinicalsarcomaresearch.com/content/4/1/2

Full metadata record

DC FieldValue Language
dc.contributor.authorMorgan, Sherifen
dc.contributor.authorNagle, Raymonden
dc.contributor.authorCranmer, Leeen
dc.date.accessioned2016-05-20T08:59:03Z-
dc.date.available2016-05-20T08:59:03Z-
dc.date.issued2014en
dc.identifier.citationMorgan et al. Clinical Sarcoma Research 2014, 4:2 http://www.clinicalsarcomaresearch.com/content/4/1/2en
dc.identifier.doi10.1186/2045-3329-4-2en
dc.identifier.urihttp://hdl.handle.net/10150/610120-
dc.description.abstractBACKGROUND:Serum protein acidic and rich in cysteine (SPARC) is a matricellular secreted glycoprotein that performs several cellular functions and has been implicated in tumorigenesis in a variety of tumor types. The chemotherapeutic agent nanoparticle albumin-encapsulated (NAB)-paclitaxel has been postulated to exploit SPARC expression to target neoplastic cells. SPARC's role, and potentially the role of NAB-paclitaxel, in the highly heterogeneous class of soft-tissue sarcomas (STS) has not been investigated. Our objective was to explore the pattern of SPARC expression and its prognostic significance in STS.METHODS:27 tissue specimens representing various STS histologies were stained for SPARC expression by immunohistochemistry (IHC). Staining intensity was scored blindly. Survival was determined from patients' medical records and analyzed using Kaplan-Meier and log-rank with respect to SPARC expression level.RESULTS:Elevated SPARC expression was observed in 15/27 (56%) specimens. Overall patient survival segregated strongly based on levels of SPARC expression. Patients who expressed low-to-moderate levels of SPARC exhibited median survival of 22.1months, while the median survival of patients with moderate-to-high expression levels was 4.4months (log ranken
dc.description.abstractp=0.0016).CONCLUSIONS:SPARC expression is elevated in a significant proportion of STS specimens analyzed in this study, but it does not appear to correlate with specific STS histologies. Given our limited sample size, we cannot draw definitive conclusions regarding association of SPARC with STS subtype. Overall survival segregates strongly by degree of SPARC expression, with elevated expression being adverse. If validated in a larger study, our results suggest that trials in STS with agents potentially targeting SPARC, such as NAB-paclitaxel, should be stratified by SPARC expression level.en
dc.language.isoenen
dc.publisherBioMed Centralen
dc.relation.urlhttp://www.clinicalsarcomaresearch.com/content/4/1/2en
dc.rights© 2014 Morgan et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0)en
dc.subjectSoft-tissue sarcomaen
dc.subjectSPARCen
dc.subjectNanoparticle albumin-encapsulated (NAB)-paclitaxelen
dc.titleSerum protein acidic and rich in cysteine (SPARC) as a prognostic marker in soft tissue sarcomasen
dc.typeArticleen
dc.identifier.eissn2045-3329en
dc.contributor.departmentThe University of Arizona Cancer Center, 1515 N. Campbell Avenue, Tucson, AZ, USAen
dc.contributor.departmentDepartment of Pathology, University of Arizona, Tucson, AZ, USAen
dc.identifier.journalClinical Sarcoma Researchen
dc.description.collectioninformationThis item is part of the UA Faculty Publications collection. For more information this item or other items in the UA Campus Repository, contact the University of Arizona Libraries at repository@u.library.arizona.edu.en
dc.eprint.versionFinal published versionen
All Items in UA Campus Repository are protected by copyright, with all rights reserved, unless otherwise indicated.